TSHA compared with FTH: revenue, margins and what each company keeps, and the suppliers and customers both name

TSHATaysha Gene Therapies, Inc.

Mkt capRevenueRevenue

FTHFaeth Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

TSHATaysha Gene Therapies, Inc.

FTHFaeth Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

TSHA

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.4%▼−4.12%×0.31

May 6 '26±14.4%▲+0.58%×0.04

Q1 FY26±12.0%▲+2.47%×0.21

Q3 FY25±22.5%▼−4.26%×0.19

FTH2 of 4 reports

Reportimpliedrealized× implied

Q3 FY26—▲+2.18%—

Q2 FY26—▼−6.73%—

= impliedTSHA realized, solidFTH realized, hatchedOne scale, both sides: full bar = 23%× = |realized| ÷ impliedspan: TSHA 281d · FTH 91dSource: market data

TSHATaysha Gene Therapies, Inc.

4.10▼−6.08%· post 4.10

Mkt cap$1.3BRevenue$5MQ4 FY25Revenue$8MFY24

FTHFaeth Therapeutics, Inc.

19.63▼−1.80%· post 19.64

ClosedNov 5 '26

Mkt cap$516.6MRevenue—Revenue—

Compare

ClosedNov 5 '26

TSHATaysha Gene Therapies, Inc.

FTHFaeth Therapeutics, Inc.

4.10▼−6.08%post 4.10

Price

19.63▼−1.80%post 19.64

$1.3B

Mkt cap

$516.6M

Q4 FY25$5M

Revenue

—

FY24$8M

Revenue

—

TSHA4.10▼−6.08%vsFTH19.63▼−1.80%ClosedNov 5 '26